Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy Study of TNX-102 SL in Participants With PTSD
NCT05372887 · Tonix Pharmaceuticals, Inc. · PHASE2 · withdrawn · last registry update 2023-12-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was stopped due to business reasons.” | – | Registry record, Tonix Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-12-09Also stopped (withdrawn): Bjorn H. Ebdrup, Pimavanserin 34 milligrams (MG) [Nuplazid] (NCT03994965)
- 2024-11-27Also stopped (terminated): State University of New York - Upstate Medical University, cyclobenzaprine ER (AMRIX) + placebo (NCT01041495)
- 2024-11-20Results posted on the registry: Christine Oryhan, Opioid Anesthetics + Non Opioid Analgesics (NCT04081545)
- 2024-07-10Also stopped (withdrawn): Centre Hospitalier St Anne, CHLORPROMAZINE (CPZ) + Standard of Care (SOC) (NCT04366739)
- 2024-07-01Phase 3 first posted: Louisiana State University Health Sciences Center Shreveport, Lumateperone 42 mg + Risperidone 2 mg (NCT06482554)
- 2024-05-28Also stopped (terminated): Assistance Publique - Hôpitaux de Paris, Intranasal midazolam + Intramuscular loxapine (NCT05324852)
- 2024-05-22Results posted on the registry: Tonix Pharmaceuticals, Inc., TNX-102 SL + Placebo SL Tablet (NCT03062540)
- 2024-05-22Also stopped (terminated): Tonix Pharmaceuticals, Inc., TNX-102 SL + Placebo SL Tablet (NCT03062540)
- 2024-05-16Results posted on the registry: Supernus Pharmaceuticals, Inc., SPN-810 (NCT02691182)
- 2024-05-16Also stopped (terminated): Supernus Pharmaceuticals, Inc., SPN-810 (NCT02691182)
- 2024-04-19Also stopped (terminated): Marubeni Pharmaceuticals (Suzhou) Co., Ltd., Lurasidone (NCT05213143)
- 2024-04-17Phase 3 first posted: State University of New York - Upstate Medical University, Dexmedetomidine + Lorazepam (NCT06370442)
- 2024-03-18Results posted on the registry: Supernus Pharmaceuticals, Inc., SPN-810 (18 mg) + SPN-810 (36 mg) (NCT02618434)
- 2024-02-28Also stopped (withdrawn): Eurofarma Laboratorios S.A., FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo + etoricoxib 90 mg (Arcoxia®) +FDC placebo (NCT05683574)
- 2024-01-31Results posted on the registry: Vanderbilt University Medical Center, Opioid Analgesic + Opioid-Free Postoperative Pain Regimen (NCT04990804)
- 2024-01-31Also stopped (terminated): Vanderbilt University Medical Center, Opioid Analgesic + Opioid-Free Postoperative Pain Regimen (NCT04990804)
- 2023-12-13Phase 3 first posted: Ain Shams University, Haloperidol Injection (NCT06168773)
- 2023-11-18Results posted on the registry: InterveXion Therapeutics, LLC, IXT-m200 + Lorazepam (NCT04715230)
- 2023-11-18Also stopped (terminated): InterveXion Therapeutics, LLC, IXT-m200 + Lorazepam (NCT04715230)
- 2023-10-05Phase 3 first posted: Tasly Pharmaceutical Group Co., Ltd, pimavanserin tartrate + placebo (NCT06068465)
- 2023-06-09Phase 3 first posted: Christian Hassager, Dexamethasone + Olanzapine (NCT05895838)
- 2023-04-07Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., Olanzapine + Haloperidol (NCT05803642)
- 2023-03-24Also stopped (withdrawn): Baylor College of Medicine, Pimavanserin (NCT04809116)
- 2023-01-19Phase 3 first posted: Alexandria University, Quatiapine + Haloperidol (NCT05690698)
- 2023-01-17Also stopped (terminated): Marubeni Pharmaceuticals (Suzhou) Co., Ltd., Lurasidone HCl + Placebo (NCT04383691)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision